Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.48 |
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.46 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414174 | 0.89 | GPR119 (0.49) | GPR119TBK1CETP | |
| SCHEMBL4655448 | 0.89 | S1PR1 (0.53) | S1PR1TBK1 | |
| SCHEMBL13602311 | 0.88 | GPR119 (0.51) | GPR119CETPPDE4APDE4BPDE4C | |
| SCHEMBL4415816 | 0.86 | CETP (0.55) | GPR119CETP | |
| SCHEMBL4412857 | 0.84 | GPR119 (0.51) | GPR119TBK1CETP | |
| SCHEMBL386184 | 0.84 | GPR119 (0.54) | GPR119TBK1IKBKECETP | |
| SCHEMBL12548315 | 0.82 | GPR119 (0.57) | GPR119CETP | |
| SCHEMBL13602338 | 0.81 | GPR119 (0.56) | GPR119CETP | |
| SCHEMBL4418527 | 0.81 | GPR119 (0.58) | GPR119CETP | |
| SCHEMBL4113375 | 0.81 | GPR119 (0.52) | GPR119S1PR1TBK1IKBKECETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885S1PR1 308/4885TBK1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.